Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza



Status:Recruiting
Conditions:Influenza
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:12 - Any
Updated:4/4/2019
Start Date:November 5, 2018
End Date:July 10, 2021
Contact:Reference Study ID Number: CP40617 www.roche.com/about_roche/roche_worldwide.htm
Email:global-roche-genentech-trials@gene.com
Phone:888-662-6728 (U.S. and Canada)

Use our guide to learn which trials are right for you!

A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza

This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in
combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir,
zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in
hospitalized patients with influenza.


Inclusion Criteria:

- Adult participants: Signed informed consent by any participant capable of giving
consent, or, where the participant is not capable of giving consent, by his or her
legal/authorized representative

- Adolescent participants not able to legally consent: written informed consent for
study participation is obtained from participant's parents or legal guardian, with
assent as appropriate by the participant, depending on the participant's level of
understanding and capability to provide assent

- Participants who require hospitalization for severe influenza or acquire influenza
during hospitalization, the severity of which requires an extension of hospitalization

- Diagnosis of influenza A and/or B by a positive Rapid Influenza Diagnostic Test (RIDT)
or reverse transcriptase-polymerase chain reaction (RT-PCR)

- The time interval between the onset of symptoms and randomization is within 96 hours

- A score of ≥4 based on the NEWS2

- Participants will require objective criteria of seriousness defined by at least one of
the following criteria:

- Requires ventilation or supplemental oxygen to support respiration

- Has a complication related to influenza that requires hospitalization (e.g.,
pneumonia, CNS involvement, myositis, rhabdomyolysis, acute exacerbation of
chronic kidney disease, asthma or chronic obstructive pulmonary disease [COPD],
severe dehydration, myocarditis, pericarditis, exacerbation of ischemic heart
disease)

- For women of childbearing potential: Agreement to remain abstinent or use
contraceptive methods with a failure rate of < 1% per year during the treatment period
and for 28 days after the last dose of study treatment. Hormonal contraceptive methods
must be supplemented by a barrier method.

Exclusion Criteria:

- Participants who have received more than 48 hours of antiviral treatment for influenza
prior to screening

- Participants who have received baloxavir marboxil for the current influenza infection

- Known contraindication to neuraminidase inhibitors

- Participants hospitalized for exclusively social reasons (e.g., lack of caregivers at
home)

- Participants expected to die or be discharged within 48 hours, according to the
investigator's judgement

- Participants weighing < 40 kg

- Participants with known severe renal impairment (estimated glomerular filtration rate
< 30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis,
peritoneal dialysis

- Participants with any of the following laboratory abnormalities detected within 24
hours prior to or during screening (according to local laboratory reference ranges:

- ALT or AST level > 5 times the upper limit of normal (ULN) OR

- ALT or AST > 3 times the ULN and total bilirubin level > 2 times the ULN

- Pregnant or breastfeeding, or positive pregnancy test in a predose examination, or
intending to become pregnant during the study or within 28 days after the last dose of
study treatment

- Exposure to an investigational drug within 5 half-lives or 30 days (whichever is
longer) of randomization

- Any serious medical condition or abnormality in clinical laboratory tests that, in the
investigator's judgment, precludes the participant's safe participation in and
completion of the study
We found this trial at
28
sites
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Annapolis, MD
Click here to add this to my saved trials
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
?
mi
from
Burlington, VT
Click here to add this to my saved trials
Butte, Montana 59701
?
mi
from
Butte, MT
Click here to add this to my saved trials
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charleston, South Carolina 29414
?
mi
from
Charleston, SC
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60637
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Dallas, Texas 75231
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials
777 Bannock St
Denver, Colorado 80204
(303) 436-6000
Denver Health Medical Center Denver Health is a comprehensive, integrated organization providing level one care...
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Greenville, North Carolina 27834
?
mi
from
Greenville, NC
Click here to add this to my saved trials
Marshfield, Wisconsin 54449
?
mi
from
Marshfield, WI
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
(414) 805-3666
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Natchitoches, Louisiana 71457
?
mi
from
Natchitoches, LA
Click here to add this to my saved trials
Newark, Delaware 19713
?
mi
from
Newark, DE
Click here to add this to my saved trials
601 N 30th St
Omaha, Nebraska 68131
(402) 449-4000
Creighton University Medical Center St. Joseph's Mercy Hospital was founded on September 25, 1870 at...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
3401 North Broad Street
Philadelphia, Pennsylvania 19140
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
2315 Stockton Blvd.
Sacramento, California 95817
(916) 734-2011
University of California, Davis Medical Center UC Davis Medical Center serves a 65,000-square-mile area that...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Salem, VA
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Staten Island, NY
Click here to add this to my saved trials
Torrance, California 90505
?
mi
from
Torrance, CA
Click here to add this to my saved trials